Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 10/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20805927 | 0.85 | P2RX7 (0.37) | CYP19A1HRH4HRH3L3MBTL1GBA1 | |
| SCHEMBL19775889 | 0.83 | CYP19A1 (0.50) | CYP19A1HRH4HRH3DRD2GBA1 | |
| SCHEMBL20805924 | 0.81 | P2RX7 (0.41) | CYP19A1 | |
| SCHEMBL1753748 | 0.79 | CYP19A1 (0.61) | CYP19A1HRH4HRH3L3MBTL1GGPS1 | |
| SCHEMBL15042747 | 0.79 | CYP19A1 (0.61) | CYP19A1HRH4HRH3L3MBTL1GGPS1 | |
| SCHEMBL16271194 | 0.79 | CYP19A1 (0.43) | CYP19A1L3MBTL1DRD2GGPS1GBA1 | |
| SCHEMBL26699502 | 0.78 | CYP19A1 (0.39) | CYP19A1HRH4HRH3L3MBTL1DRD2 | |
| SCHEMBL25623211 | 0.77 | HSP90AB1 (0.35) | CYP19A1HRH4HRH3L3MBTL1DRD2 | |
| SCHEMBL5021089 | 0.77 | CYP19A1 (0.59) | CYP19A1HRH4HRH3GBA1 | |
| SCHEMBL17249572 | 0.77 | CYP19A1 (0.41) | CYP19A1HRH4HRH3L3MBTL1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | CYP19A1 4782/4885HRH4 1548/4885HRH3 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.